Compare Medpace Holdings Inc (MEDP) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Zscaler Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Zscaler Inc trades at $148.57 (market cap $24.23B). The key difference: Zscaler Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | ZS | |
|---|---|---|
Market Cap | $15.08B | $24.23B |
Sector | Technology | Technology |
52-Week High | $620.59 | $336.27 |
52-Week Low | $308.88 | $118.05 |
Enterprise Value | $14.55B | $22.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Zscaler (ZS) trades at $150.70, up 0.54% with a bullish technical outlook. The stock shows strong revenue growth from $1.1B in 2022 to $2.67B in 2025, though remains unprofitable with a -2.44% net margin. Recent earnings consistently beat expectations, and analyst consensus is strongly bullish with a $192.46 price target. However, the company faces class action investigations and rising AI infrastructure costs that pressure margins.
ZS presents a growth opportunity in cybersecurity with Zero Trust adoption and AI security traction, but investors must weigh persistent losses against high valuation multiples. The stock's 34% YTD decline creates potential upside if execution improves, though competitive pressures and profitability concerns remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
